About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
2020 ASCO Virtual Direct™ Highlights
Boston
Breast
GYN
Lung
GI
GU
Skin
Hematologic Oncology
Head&Neck
Supportive/Palliative Care
St. Louis
Breast
GYN
Lung
GI
GU
Skin
Hematologic Oncology
Head&Neck
Supportive/Palliative Care
Basic Science
Jacksonville
Breast
Hematologic Oncology
Lung
GI
GU
GYN
Skin
Head&Neck
Basic Science
Philadelphia
GI
GU
Lung
Skin
Hematologic Oncology
Breast
Supportive/Palliative Care
Head&Neck
GYN
Denver
Breast
Hematologic Oncology
Lung
GU
Skin
GYN
Head&Neck
Basic Science
San Francisco
Breast
Lung
GU
Hematologic Oncology
Skin
GI
GYN
Head&Neck
Business
Las Vegas
GI
GU
Hematologic Oncology
Skin
Lung
Head&Neck
GYN
Business
San Juan
Breast
GI
Hematologic Oncology
Skin
GYN
Basic Science
Head and Neck
Supportive and Palliative Care
Business
Events
Head&Neck
13:07
2020 ASCO Virtual Direct™ Highlights
ASCO 2020 H&N Cancers Update: Post-Operative CRT in High-Risk Patients with SCC - What Is the Optimal Dose of Cisplatin? When Should We Use IO vs. Chemo/Cetuximab?
FEATURING
Jochen Lorch
11 views
September 17, 2020
10:13
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on Thyroid Cancers: Can the Addition of Pembro Increase Lenvatinib Efficacy? Is the Combination of Targeted Therapy + Atezo Safe? Does Targeted + IO Lead to Improved OS?
FEATURING
Jochen Lorch
16 views
September 17, 2020
06:34
2020 ASCO Virtual Direct™ Highlights
2020 ASCO Update on FDA Approved Selpercatinib in RET-Driven Thyroid Cancers: What Are the Benefits and AE? Is There Cross-Resistance with Selpercatinib and Pralsetinib?
FEATURING
Jochen Lorch
16 views
September 17, 2020
